VOR is a on daily chart. It is a biotechnology startup which is burning cash. As a resut this is
a speculative long trade for this company with products to treat leukemia ( blood cancer).
Price has crossed over the POC line of the volume profile and also completed an
anchored mean VWAP cross over. The Price Momentum Oscillator is reversing and buying
volume...
Vor Biopharma is advancing blood cancer treatments with innovative technologies, focusing on improving care for AML, MDS, and MPN by making stem cells resistant. This method has shown promise, especially for post-transplant AML treatments. Wedbush analyst David Nierengarten is optimistic about the VBP301 trial, highlighting superior outcomes with VCAR33ALLO over...
